SEC 13F Intelligence

Managers / Q1 2022 · view latest →

BAKER BROS. ADVISORS LP

CIK 0001263508 · 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK, NY, 10014 · 2123395600

Reported Value
$17.4B
Q1 2022
Positions
118
Filings on Record
30
2019–present window
Filed
May 16, 2022
original filing

Summary

Baker Bros. Advisors LP reported $17.4B in U.S.-listed holdings across 118 positions for Q1 2022.

The portfolio is heavily concentrated: SGENUSD alone accounts for 38.8% of reported value.

Compared with Q4 2021, the fund opened 2 new positions and exited 5.

Portfolio Metrics

Turnover
+3.4%
vs prior filed quarter
Top-10 Concentration
+85.0%
share of reported value
Largest Position
+38.8%
Seagen
New / Exited
2 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $12.2BQ4 ’18Q1 ’19: $15.6BQ2 ’19: $14.7BQ3 ’19: $14.7BQ4 ’19: $18.8BQ4 ’19Q1 ’20: $16.2BQ2 ’20: $22.7BQ3 ’20: $25.0BQ4 ’20: $26.5BQ4 ’20Q1 ’21: $23.1BQ2 ’21: $22.8BQ3 ’21: $22.8BQ4 ’21: $20.6BQ4 ’21Q1 ’22: $17.4BQ2 ’22: $17.6BQ3 ’22: $15.3BQ4 ’22: $16.7BQ4 ’22Q1 ’23: $18.4BQ2 ’23: $17.3BQ3 ’23: $17.4BQ4 ’23: $8.8BQ4 ’23Q1 ’24: $8.0BQ2 ’24: $7.8BQ3 ’24: $9.6BQ4 ’24: $9.4BQ4 ’24Q1 ’25: $9.0BQ2 ’25: $10.3BQ3 ’25: $13.8BQ4 ’25: $17.1BQ4 ’25Q1 ’26: $17.4Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 77.0%ADR: 15.9%Other: 6.6%US DOMESTIC: 0.5%Equity WRT: 0.0%
  • Common Stock · 77.0% · $13.4B
  • ADR · 15.9% · $2.8B
  • Other · 6.6% · $1.2B
  • US DOMESTIC · 0.5% · $85M
  • Equity WRT · 0.0% · $208,000

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VERAVera Therapeutics, Inc.NEW+333.3K333.3K+$8M$8M
EPZMEUREpizyme, Inc.NEW+1.00M1.00M+$1M$1M
HOOKIPA Pharma Inc.ADDED+1.70M2.40M+$4M$5M
BMEABiomea Fusion, Inc.ADDED+1.03M1.55M+$3M$7M
REPLReplimune Group, Inc.ADDED+1.02M1.61M+$11M$27M
TSVT*2seventy bio, Inc.ADDED+1.23M2.06M+$14M$35M
Apellis Pharmaceuticals, Inc.SOLD OUT−31.75M0−$48M$0
Tricida, Inc.SOLD OUT−27.50M0−$15M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SGENUSDSeagen Inc.history →COM38.83%$6.8B46.91M
2INCYIncyte Corporationhistory →COM16.50%$2.9B36.15M
3ONCBeiGene, Ltd.history →SPONSORED ADR12.65%$2.2B11.67M
4ACADACADIA Pharmaceuticals Inc.history →COM5.83%$1.0B41.91M
5BMRNBioMarin Pharmaceutical Inc.history →COM3.38%$588M7.62M
6Ascendis Pharma A/SSPONSORED ADR3.06%$533M4.54M
7ARGXargenx SEhistory →SPONSORED ADR2.03%$353M1.12M
8BCRXBioCryst Pharmaceuticals, Inc.history →COM1.19%$207M12.71M
9MDGLMadrigal Pharmaceuticals, Inc.history →COM0.85%$147M1.50M
10KODKodiak Sciences Inc.history →COM0.71%$123M15.93M
11MRTXEURMirati Therapeutics, Inc.history →COM0.67%$116M1.41M
12GBTUSDGlobal Blood Therapeutics, Inc.history →COM0.66%$115M3.31M
13ABCLAbCellera Biologics Inc.history →COM0.59%$102M10.45M
14KYMRKymera Therapeutics, Inc.history →COM0.58%$101M2.38M
15Horizon Therapeutics Public Ltd CoSHS0.54%$95M898.8K
16IM8NInsmed IncorporatedCOM PAR $.01 · Note 0.75% 6/1/20280.51%$89M42.16M
17TVTXTravere Therapeutics, Inc.history →COM0.49%$85M3.30M
181K0IGM Biosciences, Inc.history →COM0.48%$84M3.16M
19Invitae CorporationCOM0.45%$79M9.87M
20IMCRImmunocore Holdings plchistory →ADS0.43%$75M2.52M
21CERSCerus Corporationhistory →COM0.43%$75M13.71M
22LEGNLegend Biotech Corporationhistory →SPONSORED ADS0.42%$73M2.01M
23PRLDPrelude Therapeutics Inc.history →COM0.40%$70M10.12M
24Amarin Corporation plcSPONSORED ADR0.40%$70M21.17M
25NBIXNeurocrine Biosciences, Inc.history →COM0.36%$63M677.0K
26Merus N.V.COM0.31%$54M2.04M
27KRYSKrystal Biotech, Inc.history →COM0.31%$54M807.7K
28PACBPacific Biosciences of California, Inc.history →COM0.28%$50M5.44M
29RYTMRhythm Pharmaceuticals, Inc.history →COM0.27%$48M4.13M
30AXD2Heron Therapeutics, Inc.history →COM0.27%$47M8.13M
31TRDAEntrada Therapeutics, Inc.history →COM0.25%$44M4.70M
32Instil Bio, Inc.COM0.24%$42M3.89M
33Alkermes plcSHS0.23%$39M1.50M
34Sarepta Therapeutics, Inc.DBCV 1.5% 11/15/20240.22%$38M29.17M
35Chinook Therapeutics, Inc.COM0.22%$38M2.33M
36Verastem, Inc.COM0.22%$38M26.99M
37Aerovate Therapeutics, Inc.COM0.22%$38M2.07M
38Immatics N.V.SHS0.20%$35M4.42M
39TSVT*2seventy bio, Inc.history →COMMON STOCK0.20%$35M2.06M
40NRIXNurix Therapeutics, Inc.history →COM0.20%$34M2.45M
41Verve Therapeutics, Inc.COM0.19%$32M1.42M
42RAREUltragenyx Pharmaceutical Inc.history →COM0.19%$32M444.4K
43Kiniksa Pharmaceuticals, Ltd.COM CL A0.16%$28M2.80M
44REPLReplimune Group, Inc.history →COM0.16%$27M1.61M
45AXSMAxsome Therapeutics, Inc.history →COM0.15%$25M611.0K
46DBV Technologies S.A.SPONSORED ADR0.13%$23M14.61M
47DSGNDesign Therapeutics, Inc.history →COM0.13%$23M1.44M
48CCXIEURChemoCentryx, Inc.history →COM0.13%$23M916.9K
49XENEXenon Pharmaceuticals Inc.history →COM0.13%$23M751.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17.4B84May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$17.1B86Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$13.8B91Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$10.3B89Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$9.0B89May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$9.4B95Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$9.6B93Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$7.8B95Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$8.0B87May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$8.8B84Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$17.4B101Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$17.3B107Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$18.4B105May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$16.7B113Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$15.3B115Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$17.6B117Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$17.4B118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$20.6B121Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$22.8B122Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$22.8B120Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$23.1B126May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$26.5B126Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$25.0B120Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$22.7B114Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$16.2B110May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$18.8B99Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$14.7B109Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$14.7B103Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$15.6B96May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$12.2B93Feb 13, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.